Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial

Dave Singh, Sally Worsley, Chang-Qing Zhu, Liz Hardaker, Alison Church, Dave Singh, Sally Worsley, Chang-Qing Zhu, Liz Hardaker, Alison Church

Abstract

Background: Umeclidinium (UMEC; long-acting muscarinic antagonist) plus vilanterol (VI; long-acting beta2 agonist [LABA]) and the LABA/inhaled corticosteroid fluticasone propionate/salmeterol (FP/SAL) are approved maintenance treatments for chronic obstructive pulmonary disease (COPD). This 12-week, multicentre, double-blind, parallel-group, double-dummy study compared the efficacy and safety of these treatments in symptomatic patients with moderate-to-severe COPD with no exacerbations in the year prior to enrolment.

Methods: Patients (n = 717) were randomised 1:1 to once-daily UMEC/VI 62.5/25 mcg or twice-daily FP/SAL 500/50 mcg. Endpoints included 0-24 h weighted mean (wm) forced expiratory volume in 1 s (FEV1) (Day 84; primary), trough FEV1 (Day 85; secondary), other lung function endpoints, symptoms, quality of life (QoL) and safety.

Results: Improvements with UMEC/VI versus FP/SAL were 0.080 L (95 % confidence interval: 0.046-0.113; wmFEV1) and 0.090 L (0.055-0.125; trough FEV1) (both p < 0.001). UMEC/VI statistically significantly improved all other lung function measures versus FP/SAL. Both treatments demonstrated a clinically meaningful improvement in symptoms (Transition Dyspnoea Index ≥1 unit) and QoL (St George's Respiratory Questionnaire Total score ≥4 unit decrease from baseline) over 12 weeks. The incidence of adverse events was 28 % (UMEC/VI) and 29 % (FP/SAL); nasopharyngitis and headache were most common.

Conclusions: Once-daily UMEC/VI 62.5/25 mcg over 12 weeks resulted in significant and sustained improvements in lung function versus twice-daily FP/SAL 500/50 mcg in patients with moderate-to-severe COPD and with no exacerbations in the year prior to enrolment.

Trial registration: NCT01822899 Registration date: March 28, 2013.

Figures

Fig. 1
Fig. 1
Flow diagram for disposition of patients (CONSORT). Abbreviations: ITT, intent-to-treat; FP/SAL, fluticasone propionate/salmeterol; UMEC, umeclidinium; VI, vilanterol. aOne patient was randomised in error; this patient was a run-in failure
Fig. 2
Fig. 2
Change from baseline in FEV1 (L) over 0–24 h on Day 84 (ITT population). Data are least squares mean (95 % CI) change from baseline. Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 1 s; ITT, intent-to-treat; LS, least squares; FP/SAL, fluticasone propionate/salmeterol; UMEC, umeclidinium; VI, vilanterol
Fig. 3
Fig. 3
Change from baseline in trough FEV1 (L) (ITT population). Data are least squares mean (95 % CI) differences of change from baseline in trough FEV1 (L) at Days 28, 56, 84 and 85. Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 1 s; ITT, intent-to-treat; LS, least squares; FP/SAL, fluticasone propionate/salmeterol; UMEC, umeclidinium; VI, vilanterol

References

    1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. (2014). Accessed 17 Dec 2014.
    1. Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, Rossi A, Hutton C, Ashton VL, Stewart R, Bichel K. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–905. doi: 10.2147/COPD.S62750.
    1. Singh D. New combination bronchodilators for COPD: current evidence and future perspectives. Br J Clin Pharmacol. 2015;79:695–708. doi: 10.1111/bcp.12545.
    1. Anoro EU summary of product characteristics, 16 May 2014. (2014). Accessed 17 Dec 2014.
    1. ANORO US prescribing information, May 2014. (2014). Accessed 17 Dec 2014.
    1. Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, Church A. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145:981–91. doi: 10.1378/chest.13-1579.
    1. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107:1538–46. doi: 10.1016/j.rmed.2013.06.001.
    1. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374:1171–8. doi: 10.1016/S0140-6736(09)61298-8.
    1. Seretide EU summary of product characteristics. (2013). Accessed 17 Dec 2014.
    1. Singh D, Worsley S, Zhu C-Q, Hardaker L, Church A. Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Eur Respir J. 2014;44(Suppl 58):P290.
    1. World Medical Association Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended (latest) by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013. (2008). Accessed 17 Dec 2014.
    1. International Conference on Harmonisation Tripartite Guideline: Guidance for Good Clinical Practice E6 (R1). (1996). Accessed 17 Dec 2014.
    1. Trivedi R, Richard N, Mehta R, Church A. Umeclidinium monotherapy in patients with COPD: a randomised, placebo-controlled study. Eur Respir J. 2014;43:72–81. doi: 10.1183/09031936.00033213.
    1. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59. doi: 10.1186/1465-9921-10-59.
    1. Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2:472–86. doi: 10.1016/S2213-2600(14)70065-7.
    1. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest. 2008;134:255–62. doi: 10.1378/chest.07-2138.
    1. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D’Andrea P, Chen H, Banerji D. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1:51–60. doi: 10.1016/S2213-2600(12)70052-8.
    1. Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinault G, Lassen C. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res. 2011;12:161. doi: 10.1186/1465-9921-12-161.
    1. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775. doi: 10.1056/NEJMoa063070.
    1. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:332–8. doi: 10.1164/rccm.200712-1869OC.
    1. Yawn BP, Raphiou I, Hurley JS, Dalal AA. The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:165–78.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner